2<sup>nd</sup> Annual Young Investigators Forum in Non-Small Cell Lung Cancer
Webcast
Webcast

2nd Annual Young Investigators Forum in Non-Small Cell Lung Cancer

Not a member of My prIME? Join now for instant access.

Watch selected segments of the 2nd Annual Young Investigators Forum in NSCLC. See presentations from the brightest and best who were selected to attend, and hear lively conversation on individual treatment preferences with senior faculty members.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

5.75 AMA PRA Category 1 Credits

Release Date

Release Date

Apr 24, 2017

Expiration Date

Apr 24, 2018

CO-CHAIRS

  • Julie Brahmer, MDSidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University
    Baltimore, Maryland, United States
  • Suresh Ramalingam, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States

FACULTY

  • David Carbone, MD, PhDComprehensive Cancer Center
    Ohio State University
    Columbus, Ohio, United States
  • Ramaswamy Govindan, MDWashington University School of Medicine
    Siteman Cancer Center
    St Louis, Missouri, United States
  • Nasser Hanna, MDMelvin and Bren Simon Cancer Center
    Indiana University
    Indianapolis, Indiana, United States
  • Mark G. Kris, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Primo N. Lara, Jr, MDUniversity of California Davis Cancer Center
    Sacramento, California, United States
  • Jyoti D. Patel, MDUniversity of Chicago
    Chicago, Illinois, United States
  • Joan Schiller, MDInova Schar Cancer Institute
    Falls Church, Virginia, United States
  • Lecia V. Sequist, MDMassachusetts General Hospital Cancer Center
    Harvard Medical School
    Boston, Massachusetts, United States

KEYNOTE SPEAKER

  • Rafi Ahmed, PhDEmory University
    Atlanta, Georgia, United States

PRESENTATION SKILLS

  • Judy FortinWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States

YOUNG INVESTIGATOR PRESENTERS

  • Max Diehn, MD, PhDStanford University
    Stanford, California, United States
  • Alexander Drilon, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Justin Gainor, MDMassachusetts General Hospital
    Boston, Massachusetts, United States
  • Jarushka Naidoo, MBBChJohns Hopkins Sidney Kimmel Cancer Center
    Baltimore, Maryland, United States

CASE PRESENTERS

  • Siddhartha Devarakonda, MDWashington University in St Louis
    St Louis, Missouri, United States
  • Gregory Durm, MDIndiana University Simon Cancer Center
    Indianapolis, Indiana, United States
  • Ticiana Leal, MDUniversity of Wisconsin Carbone Cancer Center
    Madison, Wisconsin, United States
  • Meghan Mooradian, MDMassachusetts General Hospital
    Boston, Massachusetts, United States
  • Nancy Nixon, MDTom Baker Cancer Centre
    Calgary, Alberta, Canada
  • Dwight Owen, MDOhio State University
    Columbus, Ohio, United States
  • Manish Patel, DOUniversity of Minnesota
    Minneapolis, Minnesota, United States
  • Ameen Salahudeen, MD, PhDStanford School of Medicine
    Stanford, California, United States

The target audience for this activity includes medical oncologists, fellows, and other healthcare providers who treat or manage patients with lung cancer.

After successful completion of this educational activity, participants should be able to:

  • Select treatment based upon disease and patient characteristics
  • Evaluate recent data from national society meetings that have the potential to impact practice, including: immunotherapy, targeted therapies, sequencing, and combination therapy

This educational activity is supported by a grant from AstraZeneca.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

ACCME-commendation-full-color

prIME Oncology designates this enduring activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Ahmed has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Brahmer has disclosed that she has received consulting fees from Celgene, Lilly, and Merck. She has also received contracted research or research support from BMS, Merck, and MedImmune/AstraZeneca. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Campo has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Carbone has disclosed that he has received consulting fees from Ariad; AstraZeneca; Bayer Healthcare; Biocept; Biothera; Boehringer Ingelheim; Bristol Myers-Squibb; Cancer Support Community; Clovis Oncology; Genentech/Roche; Guardant Health; Inivata; Janssen Diagnostics; Merck; Novartis; Peregrine Pharmaceuticals, Inc; Pfizer; and Synta Pharmaceuticals Corp. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Devarakonda has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Diehn has disclosed that he has received consulting fees from Roche, and has received fees for contracted research or received research support from Varian. He also has ownership interest in Cibermed and patent filings related to CIDNA assigned to Stanford.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Drilon has disclosed that he has received honoraria from Ariad, AstraZeneca, Ignyta, Roche/Genentech, and Loxo. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Durm has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Judy Fortin has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Gainor has disclosed that he has received consulting fees from Ariad, BMS, Genentech, Loxo, Merck, Novartis, and Theravance. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Govindan has disclosed that he has received consulting fees from Abbvie, ARIAD, Astellas, AstraZeneca, Baxalta, BMS, Genentech, INC, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hanna has disclosed that he has performed contracted research for or received research support from Bristol Myers Squibb and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kris has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lara has disclosed that he has received honoria from Pfizer. He has also received consulting fees from Abbvie, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Halozyme, Janssen, Novartis, Pfizer, Sanofi, and Turnstone Bio. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Leal has disclosed that she has received consulting fees from Ariad and Genentech. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Naidoo has disclosed that she has received consulting fees from AstraZeneca, Bristol Myers Squibb, and Medimmune. She has also performed contracted research for or received research support from AstraZeneca, Medimmune, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Nixon has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Owen has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr J Patel has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr M Patel has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ramalingam has disclosed that he has received consulting fees from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Genentech, Lilly, Merck, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Salahudeen has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Schiller has disclosed that she has received consulting fees from Ariad, Abbvie, AstraZeneca, AVEO, Bristol Myers Squibb, Boehringer Ingelheim, Biodesix, Clovis Oncology, Dekkun, Eisai, EMD Serano, Genentech/Roche, Halozyme, Lilly Oncology, Merck, OncoGenex, Synta, and Vertex. She has also received clinical research grants from Abbvie, Astex, Clovis Oncology, EMD Serono, Endocyte, Genentech, Janssen, Johnson and Johnson, Merrimack, Novartis, Pfizer, Puma, Synta, and Xcovery. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Sequist has disclosed that she has received consulting fees from Ariad, AstraZeneca, Bristol Myers Squibb, and Genentech. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Zach Hartman, PhD (scientific content reviewer/planner) – Ownership interest in Advaxis, Inc, and Ariad Pharmaceuticals
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships